Neuropsychopharmacol:兴奋剂效果“因鼠而异”

2012-04-10 新华网 新华网

加拿大不列颠哥伦比亚大学研究人员3月28日在美国《神经精神药理学》杂志上发表报告称,他们以实验鼠为对象进行了一项刺激类药物测试。在实验中,老鼠可以选择“容易任务”或“困难任务”,选择“困难任务”并且成功通过的老鼠会得到加倍的奖励。研究人员发现,有一些老鼠选择“困难任务”的次数明显多于他们的“懒惰”同伴,研究人员将它们定义为“自我驱动强烈”的老鼠。 之后,研究人员给这两类老鼠都注射刺激类药物安非他

加拿大不列颠哥伦比亚大学研究人员3月28日在美国《神经精神药理学》杂志上发表报告称,他们以实验鼠为对象进行了一项刺激类药物测试。在实验中,老鼠可以选择“容易任务”或“困难任务”,选择“困难任务”并且成功通过的老鼠会得到加倍的奖励。研究人员发现,有一些老鼠选择“困难任务”的次数明显多于他们的“懒惰”同伴,研究人员将它们定义为“自我驱动强烈”的老鼠。

之后,研究人员给这两类老鼠都注射刺激类药物安非他明和咖啡因,结果发现,那些“自我驱动强烈”的老鼠明显松懈了下来,而原本“懒惰”的老鼠在被注射了安非他明后,表现得更勤奋了。

“从彻夜开车的卡车司机到为应对考试而熬夜复习的学生,每天都有数百万人使用含咖啡因饮料帮助自己清醒和警觉,并且提高工作效率”,此项研究的负责人杰·霍斯金说,“研究成果表明,一些兴奋剂或许会对本来就喜欢面对挑战的人带来消极影响。”(生物谷 bioon.com)

doi:10.1038/npp.2012.30
PMC:
PMID:

Sensitivity to Cognitive Effort Mediates Psychostimulant Effects on a Novel Rodent Cost/Benefit Decision-Making Task

Paul J Cocker, Jay G Hosking, James Benoit,Catharine A Winstanley

Amotivational states and insufficient recruitment of mental effort have been observed in a variety of clinical populations, including depression, traumatic brain injury, post-traumatic stress disorder, and attention deficit hyperactivity disorder. Previous rodent models of effort-based decision making have utilized physical costs whereas human studies of effort are primarily cognitive in nature, and it is unclear whether the two types of effortful decision making are underpinned by the same neurobiological processes. We therefore designed a novel rat cognitive effort task (rCET) based on the 5-choice serial reaction time task, a well-validated measure of attention and impulsivity. Within each trial of the rCET, rats are given the choice between an easy or hard visuospatial discrimination, and successful hard trials are rewarded with double the number of sugar pellets. Similar to previous human studies, stable individual variation in choice behavior was observed, with ‘workers’ choosing hard trials significantly more than their ‘slacker’ counterparts. Whereas workers ‘slacked off’ in response to administration of amphetamine and caffeine, slackers ‘worked harder’ under amphetamine, but not caffeine. Conversely, these stimulants increased motor impulsivity in all animals. Ethanol did not affect animals' choice but invigorated behavior. In sum, we have shown for the first time that rats are differentially sensitive to cognitive effort when making decisions, independent of other processes such as impulsivity, and these baseline differences can influence the cognitive response to psychostimulants. Such findings could inform our understanding of impairments in effort-based decision making and contribute to treatment development.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1787114, encodeId=5de21e871148d, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Feb 10 11:30:00 CST 2013, time=2013-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788136, encodeId=874f1e881369b, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Wed May 30 23:30:00 CST 2012, time=2012-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908141, encodeId=2efb19081412e, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Oct 25 20:30:00 CST 2012, time=2012-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995869, encodeId=40f619958695d, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Jul 16 04:30:00 CST 2012, time=2012-07-16, status=1, ipAttribution=)]
    2013-02-10 jj000001
  2. [GetPortalCommentsPageByObjectIdResponse(id=1787114, encodeId=5de21e871148d, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Feb 10 11:30:00 CST 2013, time=2013-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788136, encodeId=874f1e881369b, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Wed May 30 23:30:00 CST 2012, time=2012-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908141, encodeId=2efb19081412e, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Oct 25 20:30:00 CST 2012, time=2012-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995869, encodeId=40f619958695d, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Jul 16 04:30:00 CST 2012, time=2012-07-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1787114, encodeId=5de21e871148d, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Feb 10 11:30:00 CST 2013, time=2013-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788136, encodeId=874f1e881369b, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Wed May 30 23:30:00 CST 2012, time=2012-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908141, encodeId=2efb19081412e, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Oct 25 20:30:00 CST 2012, time=2012-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995869, encodeId=40f619958695d, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Jul 16 04:30:00 CST 2012, time=2012-07-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1787114, encodeId=5de21e871148d, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Feb 10 11:30:00 CST 2013, time=2013-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788136, encodeId=874f1e881369b, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Wed May 30 23:30:00 CST 2012, time=2012-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908141, encodeId=2efb19081412e, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Oct 25 20:30:00 CST 2012, time=2012-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995869, encodeId=40f619958695d, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Jul 16 04:30:00 CST 2012, time=2012-07-16, status=1, ipAttribution=)]
    2012-07-16 yb6560

相关资讯

Nature:研究发现与自闭症有关的三个基因突变

4月2号是第五届世界自闭症日,4月4日Nature杂志在线发表三篇作为特色文章的研究论文表明自闭症与多个基因突变有关。 三个新发现的基因突变与自闭症有关。这些研究成果揭开了自闭症的新的遗传靶标,为自闭症的重要的遗传变化及导致泛自闭障碍(autism spectrum disorders, ASD)的多个生物学途径提供了新的理解。 基因突变是发生在DNA链上的错误,使人具有患某种疾病的风险。在这

Cur Biology:生物学家确定一种防止神经退化的关键酶Nmmat

近日,国际著名杂志Current Biology在线刊登了宾夕法尼亚大学研究人员的最新研究成果,文章中,作者阐述了一个新的神经损伤的动物模型揭示了一种名为Nmnat酶在神经纤维修复和神经保护过程中的关键作用。生物学家在成年的黑腹果蝇身上发现这种模型。Nancy Bonini 说,“我们使用果蝇的基本能力去了解在严重的损伤情况下,果蝇的神经元是如何受损的。Nancy Bonini是这项研究的主要作者

Nat Neurosci:研究发现秀丽隐杆线虫应对氧浓度行为调节机制

《Nature Neuroscience》3月4日在线发表英国剑桥大学的研究人员的研究报告,该报告报道了秀丽隐杆线虫应对环境中氧浓度变化的行为调节机制。这项研究帮助我们在了解动物的持续防御行为方面迈出重要的一步。 对所有生物而言,每时每刻都有一大堆的环境信息需要应对,因此其感知系统会进化产生相应的适应机制以对大多数环境刺激作出快速反应或忽略某些刺激。一些有害刺激能在很长时间内被生物所记住,但是,

Science:灵长类动物的大脑在新扫描仪下的精细图谱

很久以来,人们认为大脑是一团缠绕的神经纤维,但研究人员最近发现,脑中的神经纤维像往右倾斜的交叉棋盘。如今,一些精妙细节作为大脑成像研究的一部分揭示了大脑的网络结构,它们借助于新的磁共振成像(MRI)扫描仪。研究结果发表在《科学》Science 期刊上。 平行的神经纤维往右倾斜形成交叉路径,进而形成2维折叠的神经层面 猴子大脑中神经纤维的3维串接图 马萨诸塞州总医院(MGH)Van W

Science:美国研究人员揭示人脑神经纤维排列方式

“编织”的大脑。图片来源:M. D. Van Wedeen 对于肉眼来说,人类大脑最显著的特点便是其波浪般的肿块和沟槽模式。 然而发表在3月30日出版的美国《Science》杂志上的一项最新研究指出,这些曲线当中实际上是由大约成直角的彼此交叉的神经纤维构成的网格(如图所示)。 研究人员利用一种新近开发出的方法——名为扩散光谱成像技术——推断了人类活体大脑中的神经纤维的位置。 这些扫描揭示了

BBRC:日本研究人员揭示大脑如何调节食欲

日本自治医科大学教授矢田俊彦率领的研究小组日前宣布,他们发现了人体进食后部分物质如何使大脑产生吃饱的感觉。进一步的研究有望让研究人员开发出新疗法治疗暴食和肥胖等病症。 此前的研究已发现,人体进食时,在作为食欲中枢的丘脑下部室旁核中,一种称为“nesfatin-1”的蛋白质会增加,让人产生吃饱感。但具体机制如何运作一直是个谜。 研究人员在小鼠身上进行实验来探究这一机制,他们从小鼠的室旁核中取出脑